P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET
Abstract BACKGROUND Characterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in...
Gespeichert in:
Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2019-09, Vol.21 (Supplement_3), p.iii73-iii73 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | iii73 |
---|---|
container_issue | Supplement_3 |
container_start_page | iii73 |
container_title | Neuro-oncology (Charlottesville, Va.) |
container_volume | 21 |
creator | Bauer, E K Stoffels, G Blau, T Reifenberger, G Werner, J M Lohmann, P Rapp, M Fink, G R Langen, K Galldiks, N |
description | Abstract
BACKGROUND
Characterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed and molecularly defined astrocytic high-grade glioma (HGG) of the WHO grades III or IV.
MATERIAL AND METHODS
Before initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean), as well as the dynamic FET PET parameters time-to-peak (TTP) and slope, were obtained. The predictive ability of FET PET parameters was evaluated with regard to the overall survival (OS). Using ROC analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for OS.
RESULTS
Sixty patients (45 GBM, 15 AA) of two university centers were retrospectively identified. Patients with a methylated MGMT promoter as well as with an IDH mutation had a significantly longer OS (both P25 minutes (AUC, 0.90; sensitivity, 90%; specificity, 87%; P |
doi_str_mv | 10.1093/neuonc/noz126.264 |
format | Article |
fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6795938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noz126.264</oup_id><sourcerecordid>10.1093/neuonc/noz126.264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1774-95c4891b335ffc84c402a09a341e799fedf55ed18eef496ba818365bf4a8be063</originalsourceid><addsrcrecordid>eNqNkF9LwzAUxYsoOKcfwLc8KpitaZM0eRFkbCoMtof5JBLSNOkibTL6Typ-eKsVwTef7oV7zuGeXxBconCGQh7PnW69U3Pn31FEZxHFR8EEkSiGhFF6_L1HkBGUnAZndf0ahhEiFE2Cjy3Cs4iDbaUzqxrrHfAG-E5XsihA3Vad7WQBrAMH2Vjtmhq82WYPSlnY3EnXgLywvpSgra3LQdY7WVoFNvAqgs-IrV6gKVpfed3s--IarmHTV36QarBd7s6DEyOLWl_8zGnwtFruFg9wvbl_XNytoUJJgiEnCjOO0jgmxiiGFQ4jGXIZY6QTzo3ODCE6Q0xrgzlNJUMspiQ1WLJUhzSeBrdj7qFNS52pocZQTxwqW8qqF15a8ffi7F7kvhM04YTHbAhAY4Aanq8rbX69KBRf_MXIX4z8xcB_8NyMHt8e_iH_BOZLjPo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><creator>Bauer, E K ; Stoffels, G ; Blau, T ; Reifenberger, G ; Werner, J M ; Lohmann, P ; Rapp, M ; Fink, G R ; Langen, K ; Galldiks, N</creator><creatorcontrib>Bauer, E K ; Stoffels, G ; Blau, T ; Reifenberger, G ; Werner, J M ; Lohmann, P ; Rapp, M ; Fink, G R ; Langen, K ; Galldiks, N</creatorcontrib><description>Abstract
BACKGROUND
Characterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed and molecularly defined astrocytic high-grade glioma (HGG) of the WHO grades III or IV.
MATERIAL AND METHODS
Before initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean), as well as the dynamic FET PET parameters time-to-peak (TTP) and slope, were obtained. The predictive ability of FET PET parameters was evaluated with regard to the overall survival (OS). Using ROC analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for OS.
RESULTS
Sixty patients (45 GBM, 15 AA) of two university centers were retrospectively identified. Patients with a methylated MGMT promoter as well as with an IDH mutation had a significantly longer OS (both P<0.001). Furthermore, ROC analysis revealed in IDH-wildtype HGG (n=45) that a TTP>25 minutes (AUC, 0.90; sensitivity, 90%; specificity, 87%; P<0.001) was highly prognostic for a longer OS (29 vs. 12 months; P<0.001). Besides a complete resection and a methylated MGMT promoter, TTP remained significant in the multivariate survival analysis (P=0.002, P=0.016, and P=0.003, respectively), indicating an independent predictor for OS. In contrast, both TBRmax and TBRmean were not prognostic (AUC, 0.37 and 0.32, respectively).
CONCLUSION
Data suggest that within the subgroup of patients with newly diagnosed and untreated IDH-wildtype GBM and AA, dynamic FET PET additionally allows the identification of patients with an improved OS.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noz126.264</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Poster Presentations</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii73-iii73</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795938/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795938/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,729,782,786,887,1586,27931,27932,53798,53800</link.rule.ids></links><search><creatorcontrib>Bauer, E K</creatorcontrib><creatorcontrib>Stoffels, G</creatorcontrib><creatorcontrib>Blau, T</creatorcontrib><creatorcontrib>Reifenberger, G</creatorcontrib><creatorcontrib>Werner, J M</creatorcontrib><creatorcontrib>Lohmann, P</creatorcontrib><creatorcontrib>Rapp, M</creatorcontrib><creatorcontrib>Fink, G R</creatorcontrib><creatorcontrib>Langen, K</creatorcontrib><creatorcontrib>Galldiks, N</creatorcontrib><title>P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract
BACKGROUND
Characterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed and molecularly defined astrocytic high-grade glioma (HGG) of the WHO grades III or IV.
MATERIAL AND METHODS
Before initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean), as well as the dynamic FET PET parameters time-to-peak (TTP) and slope, were obtained. The predictive ability of FET PET parameters was evaluated with regard to the overall survival (OS). Using ROC analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for OS.
RESULTS
Sixty patients (45 GBM, 15 AA) of two university centers were retrospectively identified. Patients with a methylated MGMT promoter as well as with an IDH mutation had a significantly longer OS (both P<0.001). Furthermore, ROC analysis revealed in IDH-wildtype HGG (n=45) that a TTP>25 minutes (AUC, 0.90; sensitivity, 90%; specificity, 87%; P<0.001) was highly prognostic for a longer OS (29 vs. 12 months; P<0.001). Besides a complete resection and a methylated MGMT promoter, TTP remained significant in the multivariate survival analysis (P=0.002, P=0.016, and P=0.003, respectively), indicating an independent predictor for OS. In contrast, both TBRmax and TBRmean were not prognostic (AUC, 0.37 and 0.32, respectively).
CONCLUSION
Data suggest that within the subgroup of patients with newly diagnosed and untreated IDH-wildtype GBM and AA, dynamic FET PET additionally allows the identification of patients with an improved OS.</description><subject>Poster Presentations</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkF9LwzAUxYsoOKcfwLc8KpitaZM0eRFkbCoMtof5JBLSNOkibTL6Typ-eKsVwTef7oV7zuGeXxBconCGQh7PnW69U3Pn31FEZxHFR8EEkSiGhFF6_L1HkBGUnAZndf0ahhEiFE2Cjy3Cs4iDbaUzqxrrHfAG-E5XsihA3Vad7WQBrAMH2Vjtmhq82WYPSlnY3EnXgLywvpSgra3LQdY7WVoFNvAqgs-IrV6gKVpfed3s--IarmHTV36QarBd7s6DEyOLWl_8zGnwtFruFg9wvbl_XNytoUJJgiEnCjOO0jgmxiiGFQ4jGXIZY6QTzo3ODCE6Q0xrgzlNJUMspiQ1WLJUhzSeBrdj7qFNS52pocZQTxwqW8qqF15a8ffi7F7kvhM04YTHbAhAY4Aanq8rbX69KBRf_MXIX4z8xcB_8NyMHt8e_iH_BOZLjPo</recordid><startdate>20190906</startdate><enddate>20190906</enddate><creator>Bauer, E K</creator><creator>Stoffels, G</creator><creator>Blau, T</creator><creator>Reifenberger, G</creator><creator>Werner, J M</creator><creator>Lohmann, P</creator><creator>Rapp, M</creator><creator>Fink, G R</creator><creator>Langen, K</creator><creator>Galldiks, N</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190906</creationdate><title>P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET</title><author>Bauer, E K ; Stoffels, G ; Blau, T ; Reifenberger, G ; Werner, J M ; Lohmann, P ; Rapp, M ; Fink, G R ; Langen, K ; Galldiks, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1774-95c4891b335ffc84c402a09a341e799fedf55ed18eef496ba818365bf4a8be063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Poster Presentations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, E K</creatorcontrib><creatorcontrib>Stoffels, G</creatorcontrib><creatorcontrib>Blau, T</creatorcontrib><creatorcontrib>Reifenberger, G</creatorcontrib><creatorcontrib>Werner, J M</creatorcontrib><creatorcontrib>Lohmann, P</creatorcontrib><creatorcontrib>Rapp, M</creatorcontrib><creatorcontrib>Fink, G R</creatorcontrib><creatorcontrib>Langen, K</creatorcontrib><creatorcontrib>Galldiks, N</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, E K</au><au>Stoffels, G</au><au>Blau, T</au><au>Reifenberger, G</au><au>Werner, J M</au><au>Lohmann, P</au><au>Rapp, M</au><au>Fink, G R</au><au>Langen, K</au><au>Galldiks, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2019-09-06</date><risdate>2019</risdate><volume>21</volume><issue>Supplement_3</issue><spage>iii73</spage><epage>iii73</epage><pages>iii73-iii73</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract
BACKGROUND
Characterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed and molecularly defined astrocytic high-grade glioma (HGG) of the WHO grades III or IV.
MATERIAL AND METHODS
Before initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean), as well as the dynamic FET PET parameters time-to-peak (TTP) and slope, were obtained. The predictive ability of FET PET parameters was evaluated with regard to the overall survival (OS). Using ROC analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for OS.
RESULTS
Sixty patients (45 GBM, 15 AA) of two university centers were retrospectively identified. Patients with a methylated MGMT promoter as well as with an IDH mutation had a significantly longer OS (both P<0.001). Furthermore, ROC analysis revealed in IDH-wildtype HGG (n=45) that a TTP>25 minutes (AUC, 0.90; sensitivity, 90%; specificity, 87%; P<0.001) was highly prognostic for a longer OS (29 vs. 12 months; P<0.001). Besides a complete resection and a methylated MGMT promoter, TTP remained significant in the multivariate survival analysis (P=0.002, P=0.016, and P=0.003, respectively), indicating an independent predictor for OS. In contrast, both TBRmax and TBRmean were not prognostic (AUC, 0.37 and 0.32, respectively).
CONCLUSION
Data suggest that within the subgroup of patients with newly diagnosed and untreated IDH-wildtype GBM and AA, dynamic FET PET additionally allows the identification of patients with an improved OS.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noz126.264</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-8517 |
ispartof | Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii73-iii73 |
issn | 1522-8517 1523-5866 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6795938 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central |
subjects | Poster Presentations |
title | P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-09T16%3A56%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P14.29%20Prediction%20of%20overall%20survival%20in%20patients%20with%20malignant%20glioma%20using%20dynamic%20O-(2-%5B18F%5D-fluoroethyl)-L-tyrosine%20PET&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Bauer,%20E%20K&rft.date=2019-09-06&rft.volume=21&rft.issue=Supplement_3&rft.spage=iii73&rft.epage=iii73&rft.pages=iii73-iii73&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noz126.264&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noz126.264%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noz126.264&rfr_iscdi=true |